News

AbbVie and Ichnos Glenmark sign licensing deal for trispecific antibody
AbbVie partners with IGI Therapeutics for ISB 2001, a potential cancer and autoimmune therapy. Read more here.
AbbVie in Immuno-Oncology Licensing Pact with IGI Therapeutics
AbbVie has struck an immuno-oncology licensing agreement with IGI Therapeutics that is potentially worth more than $1.9 billion to the clinical-stage biotechnology company.
India's Glenmark Pharma unit, Abbvie sign exclusive licensing pact
India's Glenmark Pharmaceuticals said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie have ...
Opinion
AHF: Gilead’s Greed Costs Latin America HIV Protection
AIDS Healthcare Foundation (AHF) denounces Gilead Sciences for once again excluding Latin America and the Caribbean (LAC) from affordable access to a groundbreaking HIV prevention drug, lenacapavir.
STAT1d
Gilead to provide HIV prevention drug to 2 million people in lower-income countries at cost
Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...
The Australian1d
PBS ‘not on the table’ in battle for pharmaceutical tariff exemption, despite lobbying
PhRMA said in a January submission to the US trade review that US companies were the “constant target of compulsory licensing ...